AG
GALT icon

Advisor Group’s Galectin Therapeutics GALT Stock Holding History

Advisor Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$2.29M Buy
799,846
+23,044
+3% +$80.1K 0.02% 746
2019
Q3 		$2.85M Sell
776,802
-30,373
-4% -$110K 0.02% 621
2019
Q2 		$3.35M Buy
807,175
+114,586
+17% +$496K 0.03% 550
2019
Q1 		$3.54M Buy
692,589
+18,298
+3% +$87.9K 0.03% 483
2018
Q4 		$2.31M Buy
674,291
+76,489
+13% +$365K 0.02% 579
2018
Q3 		$3.59M Sell
597,802
-15,162
-2% -$83.4K 0.04% 434
2018
Q2 		$3.9M Buy
612,964
+56,587
+10% +$276K 0.05% 316
2018
Q1 		$2.64M Buy
556,377
+25,527
+5% +$119K 0.04% 454
2017
Q4 		$1.77M Buy
530,850
+11,000
+2% +$27.8K 0.02% 605
2017
Q3 		$1.11M Buy
519,850
+35,850
+7% +$71K 0.02% 742
2017
Q2 		$1.19M Buy
484,000
+45,700
+10% +$122K 0.02% 666
2017
Q1 		$1.01M Buy
438,300
+67,475
+18% +$102K 0.02% 704
2016
Q4 		$363K Sell
370,825
-42,300
-10% -$37.6K 0.01% 1188
2016
Q3 		$467K Buy
413,125
+15,200
+4% +$27K 0.01% 1009
2016
Q2 		$584K Buy
+397,925
New +$584K 0.02% 842

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Advisor Group's GALT Position: Q4 2019 in Review

Advisor Group increased its Galectin Therapeutics (GALT) stake by 3% in Q4 2019, buying an estimated $80.1K and bringing the position to 799,846 shares worth $2.29M. The position accounts for 0.02% of the portfolio, ranked #746.

Advisor Group first reported a position in GALT in Q2 2016 and has held it in 15 quarters since. The position peaked at $3.9M in Q2 2018. 78 funds tracked by Wall St. Rank hold GALT as of Q4 2019.

  • Advisor Group held 799,846 shares of Galectin Therapeutics worth $2.29M as of Q4 2019.
  • Advisor Group bought 23,044 Galectin Therapeutics shares in Q4 2019, an estimated $80.1K.
  • Galectin Therapeutics made up 0.02% of Advisor Group's portfolio in Q4 2019, its #746 holding.
  • Advisor Group first reported a position in Galectin Therapeutics in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Galectin Therapeutics position peaked at $3.9M in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.